

# Duration of Protection against Mild and Severe Disease

New England Journal of Medicine

386, 340-350

DOI: [10.1056/nejmoa2115481](https://doi.org/10.1056/nejmoa2115481)

Citation Report

#	ARTICLE	IF	CITATIONS
4	COVID-19 Vaccination Mandates and Vaccine Uptake. SSRN Electronic Journal, 0, , .	0.4	0
8	Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England. Nature Medicine, 0, , .	15.2	6
10	Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nature Medicine, 2022, 28, 831-837.	15.2	284
13	The Unintended Consequences of COVID-19 Vaccine Policy: Why Mandates, Passports, and Segregated Lockdowns May Cause more Harm than Good. SSRN Electronic Journal, 0, , .	0.4	4
14	Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine, 2022, 28, 838-843.	15.2	85
16	Vaccine Effectiveness of Two and Three Doses of BNT162b2 and Coronavac Against COVID-19 in Hong Kong. SSRN Electronic Journal, 0, , .	0.4	26
17	Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial. SSRN Electronic Journal, 0, , .	0.4	0
18	Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets. MBio, 2022, 13, e0016922.	1.8	14
19	Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 2022, 10, 350.	2.1	44
20	Waning effectiveness of COVID-19 vaccines. Lancet, The, 2022, 399, 771-773.	6.3	35
24	â€œOmicron mildâ€? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. Journal of Medical Virology, 2022, 94, 3521-3539.	2.5	20
25	Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections. Open Forum Infectious Diseases, 2022, 9, ofac116.	0.4	15
26	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 2022, 386, 1532-1546.	13.9	1,709
27	Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infectious Diseases, 2022, 22, 311.	1.3	43
28	Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. Journal of Medical Virology, 2022, 94, 2969-2976.	2.5	191
30	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. New England Journal of Medicine, 2022, 386, 1804-1816.	13.9	311
31	SARS-CoV-2 Vaccination Coverage and Key Public Health Indicators May Explain Disparities in COVID-19 Country-Specific Case Fatality Rate Within European Economic Area. Cureus, 2022, 14, e22989.	0.2	2
32	Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave. BMC Public Health, 2022, 22, 503.	1.2	25

#	ARTICLE	IF	CITATIONS
35	Singing Is a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case-Control Study of Karaoke-Related Coronavirus Disease 2019 Outbreaks in 2 Cities in Hokkaido, Japan, Linked by Whole Genome Analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac158.	0.4	6
38	Oh Omikron!. <i>Hautnah</i> , 2022, 21, 2-3.	0.0	2
40	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	4.9	27
43	Impact of COVID-19 immunisation on COVID-19 incidence, hospitalisations, and deaths by age group in Germany from December 2020 to October 2021. <i>Vaccine</i> , 2022, 40, 2910-2914.	1.7	3
45	Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. <i>Viruses</i> , 2022, 14, 759.	1.5	41
47	Decreased severity of the Omicron variant of concern: further evidence from Italy. <i>International Journal of Infectious Diseases</i> , 2022, 119, 21-23.	1.5	8
49	Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England. <i>Journal of Infection</i> , 2022, 85, 90-122.	1.7	10
52	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
54	Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. <i>Vaccine</i> , 2022, 40, 3027-3037.	1.7	18
55	Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 226, 1863-1866.	1.9	2
56	Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination. <i>Vaccines</i> , 2022, 10, 640.	2.1	0
58	Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 487.	2.1	4
59	Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model. <i>Age and Ageing</i> , 2022, 51, .	0.7	6
61	Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. <i>Vaccines</i> , 2022, 10, 662.	2.1	17
63	Omicron surge and the future of COVID-19 vaccinations. <i>Medical Journal of Indonesia</i> , 2022, 31, 80-4.	0.2	0
64	Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2565.	1.0	52
65	Adaptive Immune Responses and Immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	39
67	Real-World Evidence "Where Are We Now?". <i>New England Journal of Medicine</i> , 2022, 386, 1680-1682.	13.9	88

#	ARTICLE	IF	CITATIONS
68	Mathematical Modelling for Optimal Vaccine Dose Finding: Maximising Efficacy and Minimising Toxicity. <i>Vaccines</i> , 2022, 10, 756.	2.1	2
69	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1131-1141.	4.6	99
70	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. <i>Molecular Therapy</i> , 2022, 30, 2952-2967.	3.7	2
71	No apparent association between mRNA COVID-19 vaccination and venous thromboembolism. <i>Blood Reviews</i> , 2022, 56, 100970.	2.8	12
72	COVID-19 Vaccine Acceptance among Social Media Users: A Content Analysis, Multi-Continent Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5737.	1.2	12
73	Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. <i>PLoS ONE</i> , 2022, 17, e0267824.	1.1	15
74	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
75	Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Caseâ€“Control Study. <i>Vaccines</i> , 2022, 10, 779.	2.1	8
76	Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. <i>American Journal of Transplantation</i> , 2022, 22, 2228-2236.	2.6	24
77	Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine. <i>Science Bulletin</i> , 2022, 67, 1326-1330.	4.3	3
78	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
80	Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. <i>Lancet Oncology</i> , The, 2022, 23, 748-757.	5.1	60
81	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. <i>BMJ Global Health</i> , 2022, 7, e008684.	2.0	122
82	A log-odds system for waning and boosting of COVID-19 vaccine effectiveness. <i>Vaccine</i> , 2022, , .	1.7	10
85	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	16
86	Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
87	COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 931-933.	4.6	133
89	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149

#	ARTICLE	IF	CITATIONS
90	Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines. <i>American Journal of Roentgenology</i> , 2022, 219, 752-761.	1.0	4
91	COVID-19 vaccination mandates and vaccine uptake. <i>Nature Human Behaviour</i> , 2022, 6, 1615-1624.	6.2	51
93	Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?. <i>Science Immunology</i> , 2022, 7, .	5.6	17
94	Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021. <i>Global Epidemiology</i> , 2022, 4, 100076.	0.6	8
95	Long Term Vaccination Strategies to Mitigate the Global Impact of SARS-CoV-2 Transmission: A Modelling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
96	Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 739-748.	5.2	82
98	Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). <i>Vaccines</i> , 2022, 10, 984.	2.1	10
99	Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium. <i>Viruses</i> , 2022, 14, 1315.	1.5	0
101	Authors'™ Reply: Clinical Studies of Vaccine Efficacy. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, ASN.2022030382.	3.0	0
102	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. <i>Nature Medicine</i> , 2022, 28, 1715-1722.	15.2	29
103	Simplified Lung Ultrasound Examination and Telehealth Feasibility in Early SARS-CoV-2 Infection. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 1047-1054.	1.2	4
104	Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination. <i>Journal of Clinical Medicine</i> , 2022, 11, 3291.	1.0	1
105	Evaluating the attitudes and behavior of Hong Kong medical students toward receiving the COVID-19 vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
106	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
107	Study authors don't consider waning SARS-CoV-2 immunity after vaccination in their model. <i>Cmaj</i> , 2022, 194, E847-E847.	0.9	1
108	Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. <i>Emerging Microbes and Infections</i> , 2022, 11, 1910-1919.	3.0	27
111	Humoral and adaptive immune responses to the SARS-CoV-2 vaccine. <i>International Journal of Infectious Diseases</i> , 2022, 122, 412-414.	1.5	0
112	Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign. <i>Journal of Medical Virology</i> , 2022, 94, 5044-5050.	2.5	27

#	ARTICLE	IF	CITATIONS
113	A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. <i>Future Virology</i> , 0, , .	0.9	4
114	Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. <i>International Journal of Infectious Diseases</i> , 2022, 122, 420-426.	1.5	10
115	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. <i>Expert Review of Vaccines</i> , 2022, 21, 1255-1268.	2.0	30
118	Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 nCoV-19 (COVISHIELD &sup>&TM&sup>) and BBV152 (COVAXINÂ®) in Previous Recipients of COVISHIELD &sup>&TM&sup> or COVAXINÂ®: A Phase 4, Participant and Observer Blinded, Randomised Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
119	Reported Effectiveness of COVID-19 Booster Vaccines: A Systematic Review of Early Literature and Implications for Emerging Vaccination Policy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
120	Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes. <i>Reproductive BioMedicine Online</i> , 2022, 45, 987-994.	1.1	8
121	Protection Against Severe Clinical Outcomes With Adenovirus or Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Patients Hospitalized With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 938-940.	1.9	1
122	Risk factors and incidence rates of COVID-19 breakthrough infections in vaccinated people with vaccine booster in general medicine, Toledo (Spain), for the period December 2021 to February 2022. <i>Archives of Community Medicine and Public Health</i> , 2022, 8, 084-091.	0.1	0
124	Neuralgic amyotrophy in COVID-19 infection and after vaccination. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 376-377.	0.2	2
127	Dawn of the hybrid immunity era in long-term care facilities. <i>The Lancet Healthy Longevity</i> , 2022, 3, e451-e452.	2.0	0
128	Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy. <i>PLoS ONE</i> , 2022, 17, e0265159.	1.1	4
129	Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies. <i>Vaccines</i> , 2022, 10, 1067.	2.1	8
130	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
131	The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1636-1643.	2.8	3
132	Comparison of the immunogenicity of five COVIDâ€19 vaccines in Sri Lanka. <i>Immunology</i> , 2022, 167, 263-274.	2.0	12
133	Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults. <i>Vaccine</i> , 2022, 40, 5050-5059.	1.7	9
134	Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1435-1443.	4.6	233
135	Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e470-e480.	2.0	22

#	ARTICLE	IF	CITATIONS
137	Rhinovirus and COVID-19 in children: a new order out of chaos?. <i>Jornal De Pediatria</i> , 2022, , .	0.9	0
138	Early report on the severity of <scp>COVID</scp>â€19 in hematologic patients infected with the <scp>SARSâ€CoV2</scp> omicron variant. <i>European Journal of Haematology</i> , 2022, 109, 364-372.	1.1	13
139	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EclinicalMedicine</i> , 2022, 50, 101529.	3.2	3
140	Parents' perceptions on COVID-19 vaccination as the new routine for their childrenâ€11â€years old. <i>Preventive Medicine</i> , 2022, 161, 107125.	1.6	14
141	Clinico-Epidemiological Characteristics of Healthcare Workers with SARS-CoV-2 Infection during the First and Second Waves in a Teaching Hospital from Eastern India: A Comparative Analysis. <i>Hospital Topics</i> , 0, , 1-12.	0.3	0
142	Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. <i>BMJ, The</i> , 0, , e071249.	3.0	31
143	Perception of COVID-19 Booster Dose Vaccine among Healthcare Workers in India and Saudi Arabia. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8942.	1.2	18
144	Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults. <i>International Journal of Cardiology</i> , 2022, 365, 41-43.	0.8	13
145	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, 1, 100015.		1
146	The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
147	COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 1161-1173.	1.5	16
148	Effectiveness of two and three mRNA COVIDâ€19 vaccine doses against Omicronâ€and Deltaâ€Related outpatient illness among adults, October 2021â€February 2022. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 975-985.	1.5	11
149	Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged â‰¥â‰65â‰years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	5
150	Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022. <i>Vaccines</i> , 2022, 10, 1215.	2.1	11
151	Uncertainties About the Optimal Timing of Fourth Dose of COVID-19 Vaccines. <i>JAMA Network Open</i> , 2022, 5, e2223096.	2.8	3
153	Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model. <i>BMJ, The</i> , 0, , e070379.	3.0	14
154	Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1856-1864.	1.4	11
155	Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1217.	2.1	3

#	ARTICLE	IF	CITATIONS
156	A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
158	COVID-19 and vaccination: myths vs science. <i>Expert Review of Vaccines</i> , 2022, 21, 1603-1620.	2.0	23
159	Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study. <i>Clinical Infectious Diseases</i> , 2023, 76, 640-648.	2.9	7
160	Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 673-680.	0.9	6
161	Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. <i>Nature Communications</i> , 2022, 13, .	5.8	34
162	Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months. <i>JAMA Network Open</i> , 2022, 5, e2226046.	2.8	11
164	Non-pharmacological interventions of travel restrictions and cancelation of public events had a major reductive mortality affect during pre-vaccination coronavirus disease 2019 period. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
165	BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	29
167	Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2) <i>Tj ETQq0 0 0 2gBT /Overlock 10 Tf e108-e115.</i>	2.8	10
169	Dynamics and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
170	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
171	Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study. <i>Vaccine</i> , 2022, 40, 5675-5682.	1.7	2
173	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	12
176	Attitudes towards COVID-19 Booster Vaccines, Vaccine Preferences, Child Immunization, and Recent Issues in Vaccination among University Students in Jordan. <i>Vaccines</i> , 2022, 10, 1258.	2.1	3
177	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
178	Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months. <i>Pediatrics</i> , 0, , .	1.0	6
179	Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. <i>MBio</i> , 2022, 13, .	1.8	18
180	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56



#	ARTICLE	IF	CITATIONS
181	The importance of booster vaccination in the context of Omicron wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
183	The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain). <i>Preventive Medicine</i> , 2022, 163, 107237.	1.6	5
184	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. <i>International Journal of Infectious Diseases</i> , 2022, 123, 183-191.	1.5	8
185	SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 1999-2008.	2.0	12
186	Immune system diversity against SARS-CoV-2 infection and vaccines. , 2022, 1, 153.		0
187	Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	2
188	The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
189	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq1 1 0.784314 rgBT <sub>2</sub> /Overlo	0.4	0
190	Will New Variants Emerge after Delta and Omicron?. , 2022, 13, 1317.		1
191	Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. <i>Nature Communications</i> , 2022, 13, .	5.8	89
193	Does providing free internet access to low-income households affect COVID-19 spread?. <i>Health Economics (United Kingdom)</i> , 0, , .	0.8	0
194	Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers. <i>Vaccine</i> , 2022, 40, 7195-7200.	1.7	17
196	Rate of True-Positive Findings of COVID-19 Typical Appearance at Chest CT per RSNA Consensus Guidelines in an Increasingly Vaccinated Population. <i>Radiology</i> , 2023, 306, .	3.6	7
197	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
198	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 2383-2392.	3.0	44
200	Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up. <i>BMJ Open</i> , 2022, 12, e065897.	0.8	5
201	The way forward to achieve high COVID-19 vaccination and revaccination coverage in a city amid a period of tranquility. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
202	Split dosing of coronavirus disease 2019 vaccines provides noninferior antibody responsiveness to conventional vaccine dosing. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, , .	0.5	1

#	ARTICLE	IF	CITATIONS
203	Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study. <i>Arthritis and Rheumatology</i> , 2023, 75, 122-132.	2.9	5
204	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1639.	2.1	1
205	Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. <i>Clinical Infectious Diseases</i> , 2023, 76, 252-262.	2.9	7
206	Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
207	Investigation of Possible Factors Influencing the Neutralizing Anti-SARS-CoV-2 Antibody Titer after Six Months from the Second Vaccination Dose in a Sample of Italian Nursing Home Personnel. <i>Antibodies</i> , 2022, 11, 59.	1.2	3
208	Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6-14 months follow-up. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 2249-2254.	1.2	8
209	Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
210	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10374.	1.8	10
211	Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021. <i>BMC Medicine</i> , 2022, 20, .	2.3	28
212	Estimating conditional vaccine effectiveness. <i>European Journal of Epidemiology</i> , 2022, 37, 885-890.	2.5	2
213	Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	7
214	Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. <i>BMJ</i> , The, 0, , e072141.	3.0	82
215	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. <i>Cell Reports</i> , 2022, 41, 111544.	2.9	17
217	Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
218	An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .	2.8	8
219	Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. <i>Nature Communications</i> , 2022, 13, .	5.8	15
220	Household transmission of the Delta COVID-19 variant in Queensland, Australia: a case series. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	5
221	BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12-17 years in Scotland. <i>Lancet Regional Health - Europe</i> , The, 2022, 23, 100513.	3.0	8

#	ARTICLE	IF	CITATIONS
222	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
223	Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. British Journal of Cancer, 2022, 127, 1827-1836.	2.9	18
224	Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study. Vaccines, 2022, 10, 1706.	2.1	3
225	SARS-CoV-2â€”The Role of Natural Immunity: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 6272.	1.0	12
226	Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells. JCI Insight, 2022, 7, .	2.3	15
227	Modeling the spatio-temporal spread of COVID-19 cases, recoveries and deaths and effects of partial and full vaccination coverage in Canada. Scientific Reports, 2022, 12, .	1.6	0
228	Comparison of Clinical Course of Covid 19 Infections in Vaccinated and Unvaccinated Individuals. International Journal of Pharmaceutical Sciences Review and Research, 0, , 61-65.	0.1	0
229	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science, 2022, 29, .	2.6	77
230	Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers. Vaccines, 2022, 10, 1741.	2.1	6
231	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS ONE, 2022, 17, e0263861.	1.1	12
233	Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. Journal of Travel Medicine, 2022, 29, .	1.4	4
234	New French guidelines to adapt the 'isolate/Detect/Trace' strategy for COVID-19 adult peoples or contacts considering the exponential spread of Omicron variant. Health Science Reports, 2022, 5, .	0.6	0
235	Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. Npj Vaccines, 2022, 7, .	2.9	12
236	Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. JAMA Network Open, 2022, 5, e2240037.	2.8	26
237	Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV. Aids, 2022, 36, F17-F26.	1.0	13
238	Anticuerpos postvacunales frente a SARS-CoV-2 en una cohorte de trabajadores de un hospital general. Archivos De Prevencio&#x0301;n De Riesgos Laborales, 2022, 25, 358-378.	0.1	2
239	Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies. MBio, 0, , .	1.8	3
240	Waning immunity to SARS-CoV-2 following vaccination or infection. Frontiers in Medicine, 0, 9, .	1.2	13

#	ARTICLE	IF	CITATIONS
241	Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales. <i>International Journal of Epidemiology</i> , 2023, 52, 22-31.	0.9	9
242	Parents' willingness to vaccinate themselves and their children with the booster vaccine against SARS-CoV-2: A cross-sectional study in Puyang city, China. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	7
243	In-silico evaluation of adenoviral COVID-19 vaccination protocols: Assessment of immunological memory up to 6 months after the third dose. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
244	Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children's medical center in Shanghai, China. <i>World Journal of Pediatrics</i> , 2023, 19, 87-95.	0.8	7
245	Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort. <i>Journal of Infectious Diseases</i> , 2022, 226, 1924-1933.	1.9	10
246	The Covid-19 Decision Support System (C19DSS) – A Mobile App. <i>Lecture Notes in Networks and Systems</i> , 2023, , 23-30.	0.5	1
249	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
250	Humoral and cellular response to the COVID-19 vaccine in immunocompromised children. <i>Pediatric Research</i> , 2023, 94, 200-205.	1.1	6
251	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. <i>Vaccines</i> , 2022, 10, 1924.	2.1	8
252	Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e063919.	0.8	8
253	High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	24
254	Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents. <i>Emerging Infectious Diseases</i> , 2022, 28, 2165-2170.	2.0	13
255	SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
256	COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
257	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
258	A Tale of 2 mRNA Vaccines. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1909-1911.	1.2	0
260	Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario. <i>Cancers</i> , 2022, 14, 5512.	1.7	6
261	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5

#	ARTICLE	IF	CITATIONS
262	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1948.	2.1	3
263	Challenges and Opportunities for Global Genomic Surveillance Strategies in the COVID-19 Era. <i>Viruses</i> , 2022, 14, 2532.	1.5	11
264	Effects of hydrometeorological and other factors on SARS-CoV-2 reproduction number in three contiguous countries of tropical Andean South America: a spatiotemporally disaggregated time series analysis. <i>IJID Regions</i> , 2023, 6, 29-41.	0.5	6
265	Continued demographic shifts in hospitalised patients with COVID-19 from migrant workers to a vulnerable and more elderly local population at risk of severe disease. <i>International Journal of Infectious Diseases</i> , 2023, 127, 77-84.	1.5	3
266	Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case-control study. <i>Lancet Regional Health - Europe</i> , The, 2023, 25, 100552.	3.0	11
267	COVID-19 endgame: From pandemic to endemic? Vaccination, reopening and evolution in low- and high-vaccinated populations. <i>Journal of Theoretical Biology</i> , 2023, 559, 111368.	0.8	29
268	Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominance. <i>American Journal of Infection Control</i> , 2022, , .	1.1	1
270	Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
271	Comparing the demographics and laboratory biomarkers of the COVID-19 Omicron wave and the Alpha wave in a predominantly Afro-Caribbean patient population in New York City. <i>Pneumonia (Nathan Qld)</i> , 2022, 14, .	2.5	1
272	Using mechanistic model-based inference to understand and project epidemic dynamics with time-varying contact and vaccination rates. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
273	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	2
274	Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients. <i>Viruses</i> , 2022, 14, 2728.	1.5	3
275	Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers. <i>Vaccines</i> , 2022, 10, 2125.	2.1	0
276	Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 2146.	2.1	4
277	Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases. <i>Journal of Autoimmunity</i> , 2023, 135, 102981.	3.0	5
278	International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2022, 23, e544-e551.	5.1	6
279	Effective screening strategies for safe opening of universities under Omicron and Delta variants of COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
280	Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 421-434.	4.6	24

#	ARTICLE	IF	CITATIONS
281	Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review. <i>Life</i> , 2022, 12, 2057.	1.1	9
282	Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. <i>Nature Communications</i> , 2022, 13, .	5.8	18
283	Effectiveness of fourth dose of COVID-19 vaccine against the Omicron variant compared with no vaccination. <i>International Journal of Epidemiology</i> , 0, , .	0.9	0
284	Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022. <i>Vaccine</i> , 2023, 41, 290-293.	1.7	6
286	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. <i>Nature Reviews Immunology</i> , 2023, 23, 381-396.	10.6	61
287	Hybrid immunity and protection against infection during the Omicron wave in Malta. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	2
288	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
290	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
291	Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. <i>Vaccines</i> , 2022, 10, 2074.	2.1	3
292	Differences in BNT126b2 and ChAdOx1 Homologous Vaccination Antibody Response among Teachers in Poznan, Poland. <i>Vaccines</i> , 2023, 11, 118.	2.1	0
293	The benefits and costs of U.S. employer COVID-19 vaccine mandates. <i>Risk Analysis</i> , 2023, 43, 2053-2068.	1.5	1
294	Death from COVID-19 in a Fully Vaccinated Subject: A Complete Autopsy Report. <i>Vaccines</i> , 2023, 11, 142.	2.1	3
295	mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	32
296	Neutralizing antibodies against SARS-CoV-2 in Brazilian pregnant women vaccinated with one or two doses of BNT162b2 mRNA vaccine (Pfizer/WyethTM). <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
297	Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. <i>Nature Aging</i> , 2023, 3, 82-92.	5.3	23
299	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
300	The Relationship of COVID-19 Vaccination with Mortality Among 86,732 Hospitalized Patients: Subpopulations, Patient Factors, and Changes over Time. <i>Journal of General Internal Medicine</i> , 2023, 38, 1248-1255.	1.3	10
301	Covid-19 vaccine effectiveness against general SARS-CoV-2 infection from the omicron variant: A retrospective cohort study. <i>PLOS Global Public Health</i> , 2023, 3, e0001111.	0.5	4

#	ARTICLE	IF	CITATIONS
302	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
303	The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. <i>EBioMedicine</i> , 2023, 88, 104430.	2.7	19
304	SARS-CoV-2 Infection in Winter 2021/2022: The Association of Varying Clinical Manifestations With and Without Prior Vaccination. <i>Cureus</i> , 2022, , .	0.2	0
305	Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily. <i>Healthcare (Switzerland)</i> , 2023, 11, 305.	1.0	3
306	Association of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID-19 Disease. <i>Critical Care Research and Practice</i> , 2023, 2023, 1-8.	0.4	0
307	Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELDâ„„) and BBV152 (COVAXINÂ®): a non-inferiority phase 4, participant and observer-blinded, randomised study. , 2023, 12, 100141.		14
308	COVID-19 Infection and Acute Pancreas Transplant Graft Thrombosis. <i>Cureus</i> , 2023, , .	0.2	0
309	Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: the prospective cohort study of the Italian obstetric surveillance system. <i>Clinical Microbiology and Infection</i> , 2023, 29, 772-780.	2.8	5
310	Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
311	SARS-CoV-2 Vaccination and Clinical Presentation of COVID-19 in Patients Hospitalized during the Delta- and Omicron-Predominant Periods. <i>Journal of Clinical Medicine</i> , 2023, 12, 961.	1.0	1
312	SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers. <i>Viruses</i> , 2023, 15, 751.	1.5	3
313	Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. <i>Process Biochemistry</i> , 2023, 127, 66-81.	1.8	9
314	Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study. <i>The Lancet Global Health</i> , 2023, 11, e759-e769.	2.9	2
315	Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2â€”seropositive individuals. , 2023, 2, 100083.		2
316	Clinical observation of neutralizing antibody DXPâ€”604 for treatment critical COVIDâ€”19 patients infected with SARSâ€”CoVâ€”2 Delta variant. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
317	COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021â€”2022: a test-negative caseâ€”control study. <i>Public Health</i> , 2023, 218, 84-91.	1.4	1
318	Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias. <i>American Journal of Epidemiology</i> , 2023, 192, 895-907.	1.6	6
320	Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. , 2023, 2, e000373.		14

#	ARTICLE	IF	CITATIONS
321	Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data. <i>Journal of Nutrition, Health and Aging</i> , 2023, 27, 81-88.	1.5	4
322	Is it bad, is it good, or is IgG4 just misunderstood?. <i>Science Immunology</i> , 2023, 8, .	5.6	10
323	Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
324	Hesitancy to Receive the Second COVID-19 Vaccine Booster Dose among Older Adults in Hong Kong: A Random Telephone Survey. <i>Vaccines</i> , 2023, 11, 392.	2.1	6
325	Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study. <i>Lancet Public Health</i> , The, 2023, 8, e174-e183.	4.7	8
326	The impacts of SARS-CoV-2 vaccine dose separation and targeting on the COVID-19 epidemic in England. <i>Nature Communications</i> , 2023, 14, .	5.8	8
327	Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 439-452.	5.2	69
328	Risk factor analysis of omicron patients with mental health problems in the Fangcang shelter hospital based on psychiatric drug intervention during the COVID-19 pandemic in Shanghai, China. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	1
329	Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19. <i>Npj Vaccines</i> , 2023, 8, .	2.9	2
331	Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3703.	1.2	2
333	Impact of COVID-19 vaccination on COVID-19 hospital admissions in England during 2021: an observational study. <i>Journal of the Royal Society of Medicine</i> , 0, , 014107682311570.	1.1	1
334	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
335	COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100461.	1.5	8
336	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). <i>Expert Review of Vaccines</i> , 2023, 22, 288-298.	2.0	4
337	Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by transairway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	1
338	The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100465.	1.5	6
339	Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. <i>JAMA Network Open</i> , 2023, 6, e232598.	2.8	31
340	Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. <i>Expert Review of Vaccines</i> , 2023, 22, 341-365.	2.0	4



#	ARTICLE	IF	CITATIONS
343	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. <i>IScience</i> , 2023, 26, 106457.	1.9	3
344	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. <i>Nature Communications</i> , 2023, 14, .	5.8	31
346	Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
348	Perceived Norms and Vaccination against COVID-19 among the General Adult Population in Germany: Results of a Nationally Representative Survey. <i>Vaccines</i> , 2023, 11, 800.	2.1	0
349	Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico. <i>Vaccines</i> , 2023, 11, 842.	2.1	0
350	Does the SARS-CoV-2 spike really have an Achilles heel?. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	0
351	Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022. <i>Medical Science Monitor</i> , 0, 29, .	0.5	0
352	The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022. <i>Osong Public Health and Research Perspectives</i> , 2023, 14, 76-88.	0.7	2
353	Development of Adenovirus-Based Covid-19 Vaccine Candidate in Indonesia. <i>Molecular Biotechnology</i> , 2024, 66, 222-232.	1.3	0
354	COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	2
357	What has vaccination against COVID-19 in CKD patients taught us?. <i>Journal of Nephrology</i> , 2023, 36, 1257-1266.	0.9	1
367	COVID-19 Vaccination in Persons with Diabetes: How to Approach Patients. <i>Contemporary Endocrinology</i> , 2023, , 179-193.	0.3	0
393	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	2.8	13
476	Combat COVID-19 at National Level using Risk Stratification with Appropriate Intervention. , 2023, , .		0